Biomatrica

Last updated
Biomatrica
Company type Subsidiary
IndustryBiotechnology
Founded2004;20 years ago (2004)
Headquarters
San Diego, California
,
United States
Area served
Worldwide
Parent Exact Sciences
Website biomatrica.com

Biomatrica is a United States-based biotechnology company, and subsidiary of Exact Sciences Corporation, that develops chemicals for ambient temperature preservation of biological materials for the purpose of expanding the availability and accuracy of medical diagnostics and research. Specifically, the company focuses on improving the stability of biological materials, such as DNA, RNA, proteins, cells from patient samples used in research, and diagnostic testing reagents. Company scientists have developed alternatives to existing preservation technologies, such as cold storage and lyophilization (freeze-drying), to prevent degradation of perishable biological materials. Biomatrica's technologies are used in applications such as pre-analytic sample collection, diagnostic assays, biobanking, forensics, and basic research. [1]

Contents

History

Biomatrica was founded by scientists, Judy Müller-Cohn, PhD, and Rolf Müller, PhD, in 2004. Prior to founding Biomatrica, both had worked many years in San Diego's biotechnology industry. Müller-Cohn had previously worked at Digital Gene Technologies and Mycogen/ Dow Agrosciences, whilst Müller had worked on the HIV Core Program Project Grant at San Diego's Scripps Research Institute. [2] [3]

Biomatrica initially developed ambient temperature storage reagents for DNA and RNA. The company's core technology was inspired by the phenomenon of anhydrobiosis, the ability of some organisms to hibernate in a desiccated state during dry periods, and then reanimate upon contact with water. [2] Focusing on microscopic, desert-dwelling creatures called Tardigrades, which undergo anhydrobiosis for up to 120 years, Biomatrica identified how to chemically mimic the mechanism of anhydrobiosis. [4] Following stabilization at room temperature with Biomatrica's chemical reagents, biological specimens could be rehydrated for subsequent studies with the addition of a few drops of water.

Since 2012, the company has become increasingly focused on its pre-analytic collection and assay stabilization service businesses described below.

In October 2018 Biomatrica was acquired by the Madison, Wisconsin-based molecular diagnostics and cancer screening company Exact Sciences Corporation for $20 million. [5]

Products and Services

The company's first product was a dry, synthetic polymer, "DNAstable" (originally “SampleMatrix”), a chemical formulation that stabilized purified DNA at ambient temperature. [6] The company later released RNAstable and CloneStable, dry chemical reagents optimized for stabilizing purified RNA and bacterial plasmid DNA, respectively. [7]

In 2007, the German biotechnology company, Qiagen, licensed DNAstable for sale under the trade name QIAsafe. Biomatrica and Qiagen subsequently co-developed QIAsafe Blood, an ambient temperature stabilization reagent for unpurified DNA in whole blood. [8] [9] Later in 2007, Biomatrica released molecular assay enhancement products, PCRboost and STRboost, for enhancement of PCR performed on degraded and trace DNA samples. [7] Liquid versions of DNAstable and RNAstable were launched as DNAstable LD and RNAstable LD in 2011 and 2012, respectively. These liquid products provide more flexibility for diverse experimental formats, including those utilizing automated instrumentation. [7]

Biomatrica began commercialization of preanalytical products in 2009 with the launch of its “gard” product line. These products include RNAgard Blood, DNAgard Blood, and DNAgard Tissue and Cells, products designed to stabilize biological samples from collection to analytical testing. [7] In 2013, the company launched a device, DNAgard Saliva, for the collection of salivary DNA samples to be used in a variety of research studies. In 2015, a completely redesigned and improved version of this device was launched under the name DNAgard Saliva HT. This new version is designed and optimized for use by high-throughput laboratory automation instruments. In 2017, the company launched LBgard Blood Tubes, which allow collection and preservation of cfDNA for 14 days, and CTCs and WBCs for 4 days, for liquid biopsy and NIPT applications.

In 2012, the company began offering custom stabilization services to diagnostic assay manufacturers under the trade name, AssayStable. This service allowed improved manufacturing and stability of diagnostic test kits. After completing several successful contracts with large diagnostic manufacturers, the company launched a related service, PCRstable, that focused specifically on improving stability of PCR-based, molecular diagnostic assays, including those using microfluidic chips and specialized cartridges and cassettes. [10] To facilitate testing and adoption of the company's stabilizers, Biomatrica launched the ReadyDry PCR Stabilizer Screening Kit in 2016.

Partnerships and Agreements

Licensing agreements for Biomatrica technologies were signed with Qiagen in 2007 and 2009. [9]

Following the launch of DNAstable, the company gained the interest of law enforcement organizations, such as the California Department of Justice, which sought to stabilize DNA samples from crime scenes for forensics purposes. Other law enforcement organizations, including sheriffs’ departments in Orange County, CA Los Angeles, CA, and Palm Beach, FL, have adopted ambient temperature forensic sample management systems based on Biomatrica's technologies. [2]

Also in 2010, Biomatrica signed a collaborative research and development agreement (CRADA) with United States Army Medical Research Institute for Infectious Diseases (USAMRIID) to develop and test new technologies for ambient temperature stabilization of clinical and biological samples. [11]

The same year, Biomatrica began a partnership agreement with the U.S. National Cancer Institute (NCI) for biomarker stabilization and SAIC-Frederick to improve molecular analysis of tumors. [12]

In 2011, the company announced a partnership agreement with In-Q-Tel, an investment firm that identifies technologies to support the mission of the U.S. intelligence community. [13]

In 2014, Biomatrica and American Type Tissue Culture (ATCC) signed a licensing agreement for Biomatrica to supply its DNA & RNA stabilization reagents to the ATCC for use in the latter company's DNA and RNA standards. [14] In the same year, Biomatrica and Sigma-Aldrich signed an agreement for the worldwide distribution of Biomatrica's stabilization reagents. [15]

Corporate governance

Related Research Articles

<span class="mw-page-title-main">Polymerase chain reaction</span> Laboratory technique to multiply a DNA sample for study

The polymerase chain reaction (PCR) is a method widely used to make millions to billions of copies of a specific DNA sample rapidly, allowing scientists to amplify a very small sample of DNA sufficiently to enable detailed study. PCR was invented in 1983 by American biochemist Kary Mullis at Cetus Corporation. Mullis and biochemist Michael Smith, who had developed other essential ways of manipulating DNA, were jointly awarded the Nobel Prize in Chemistry in 1993.

Viral load, also known as viral burden, is a numerical expression of the quantity of virus in a given volume of fluid, including biological and environmental specimens. It is not to be confused with viral titre or viral titer, which depends on the assay. When an assay for measuring the infective virus particle is done, viral titre often refers to the concentration of infectious viral particles, which is different from the total viral particles. Viral load is measured using body fluids sputum and blood plasma. As an example of environmental specimens, the viral load of norovirus can be determined from run-off water on garden produce. Norovirus has not only prolonged viral shedding and has the ability to survive in the environment but a minuscule infectious dose is required to produce infection in humans: less than 100 viral particles.

Affymetrix is now Applied Biosystems, a brand of DNA microarray products sold by Thermo Fisher Scientific that originated with an American biotechnology research and development and manufacturing company of the same name. The Santa Clara, California-based Affymetrix, Inc. now a part of Thermo Fisher Scientific was co-founded by Alex Zaffaroni and Stephen Fodor. Stephen Fodor and his group, based on their earlier development of methods to fabricate DNA microarrays using semiconductor manufacturing techniques.

Invitrogen is one of several brands under the Thermo Fisher Scientific corporation. The product line includes various subbrands of biotechnology products, such as machines and consumables for polymerase chain reaction, reverse transcription, cloning, culturing, stem cell production, cell therapy, regenerative medicine, immunotherapy, transfection, DNA/RNA purification, diagnostic tests, antibodies, and immunoassays.

<span class="mw-page-title-main">ATCC (company)</span>

ATCC or the American Type Culture Collection is a nonprofit organization which collects, stores, and distributes standard reference microorganisms, cell lines and other materials for research and development. Established in 1925 to serve as a national center for depositing and distributing microbiological specimens, ATCC has since grown to distribute in over 150 countries. It is now the largest general culture collection in the world.

Sigma-Aldrich is an American chemical, life science, and biotechnology company owned by the multinational chemical conglomerate Merck Group.

<span class="mw-page-title-main">Qiagen</span> German biotechnology company

QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in respectively Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer (CEO).

<span class="mw-page-title-main">Real-time polymerase chain reaction</span> Laboratory technique of molecular biology

A real-time polymerase chain reaction is a laboratory technique of molecular biology based on the polymerase chain reaction (PCR). It monitors the amplification of a targeted DNA molecule during the PCR, not at its end, as in conventional PCR. Real-time PCR can be used quantitatively and semi-quantitatively.

<span class="mw-page-title-main">New England Biolabs</span> American life sciences company

New England Biolabs (NEB) is an American life sciences company which produces and supplies recombinant and native enzyme reagents for life science research. It also provides products and services supporting genome editing, synthetic biology and next-generation sequencing. NEB also provides free access to research tools such as REBASE, InBASE, and Polbase.

Ionian Technologies Inc. was a United States Biotechnology Company focused on molecular diagnostics development for the detection of infectious diseases and biothreat agents. It was established in 2000 in Upland, California as the first spin-off company to commercialize technology developed at the Keck Graduate Institute. Since its inception Ionian has expanded its isothermal amplification technology. Ionian was acquired in July 2010 by Alere Inc.

Biomolecular engineering is the application of engineering principles and practices to the purposeful manipulation of molecules of biological origin. Biomolecular engineers integrate knowledge of biological processes with the core knowledge of chemical engineering in order to focus on molecular level solutions to issues and problems in the life sciences related to the environment, agriculture, energy, industry, food production, biotechnology and medicine.

<span class="mw-page-title-main">Nucleic acid test</span> Group of techniques to detect a particular nucleic acid sequence

A nucleic acid test (NAT) is a technique used to detect a particular nucleic acid sequence and thus usually to detect and identify a particular species or subspecies of organism, often a virus or bacterium that acts as a pathogen in blood, tissue, urine, etc. NATs differ from other tests in that they detect genetic materials rather than antigens or antibodies. Detection of genetic materials allows an early diagnosis of a disease because the detection of antigens and/or antibodies requires time for them to start appearing in the bloodstream. Since the amount of a certain genetic material is usually very small, many NATs include a step that amplifies the genetic material—that is, makes many copies of it. Such NATs are called nucleic acid amplification tests (NAATs). There are several ways of amplification, including polymerase chain reaction (PCR), strand displacement assay (SDA), or transcription mediated assay (TMA).

QIAGEN Silicon Valley is a company based in Redwood City, California, USA, that develops software to analyze complex biological systems. QIAGEN Silicon Valley's first product, IPA, was introduced in 2003, and is used to help researchers analyze omics data and model biological systems. The software has been cited in thousands of scientific molecular biology publications and is one of several tools for systems biology researchers and bioinformaticians in drug discovery and institutional research.

Eurogentec is a biotechnology supplier, based in Belgium, that specializes in genomics and proteomics kits, reagents, and certain biologics. It was founded in 1985 as a spin-off from the University of Liège. Eurogentec operates two licensed contract manufacturing organization facilities in Belguim which produce custom biologic and oligonucleotide products mainly for European pharmaceutical companies, but also holds a license from the U.S. FDA to export a commercial protein product to the U.S.. These products are used to diagnose and treat various conditions.

Immudex is a Danish Reagents and Diagnostics company established in 2009. The company is operating from offices located in Copenhagen, Denmark, and in Fairfax, Virginia. Immudex specializes in the production of MHC Dextramers. MHC Dextramers are chemical reagents that are designed to detect antigen-specific T cells.

<span class="mw-page-title-main">Molecular diagnostics</span> Collection of techniques used to analyze biological markers in the genome and proteome

Molecular diagnostics is a collection of techniques used to analyze biological markers in the genome and proteome, and how their cells express their genes as proteins, applying molecular biology to medical testing. In medicine the technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients, and in agricultural biosecurity similarly to monitor crop- and livestock disease, estimate risk, and decide what quarantine measures must be taken.

DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics and since July 2021, it is also active in the Life Science business. The group was founded in 2000 and is headquartered in Saluggia, Italy. Its production is at several plants located in Europe and the United States: Saluggia and Gerenzano (Italy), Dietzenbach (Germany), Stillwater, Minnesota (US), Dartford (UK). Following the acquisition of Luminex, the company acquired five additional production plants located in the United States and in Canada (Toronto). The company is a constituent of the FTSE MIB index.

<span class="mw-page-title-main">Exact Sciences Corp.</span> American company in Madison, United States

Exact Sciences Corp. is a molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer.

Creative Diagnostics is an American biotechnology company that specializes in the research and manufacturing of antibodies, viral antigens, diagnostic components, and critical assay reagents.

Clinical metagenomic next-generation sequencing (mNGS) is the comprehensive analysis of microbial and host genetic material in clinical samples from patients by next-generation sequencing. It uses the techniques of metagenomics to identify and characterize the genome of bacteria, fungi, parasites, and viruses without the need for a prior knowledge of a specific pathogen directly from clinical specimens. The capacity to detect all the potential pathogens in a sample makes metagenomic next generation sequencing a potent tool in the diagnosis of infectious disease especially when other more directed assays, such as PCR, fail. Its limitations include clinical utility, laboratory validity, sense and sensitivity, cost and regulatory considerations.

References

  1. ↑ "Biomatrica, Inc". SBA. Retrieved 21 June 2018.
  2. 1 2 3 Steve Chapple (December 4, 2011). "Nothing frozen in Biomatrica's storage process". San Diego Union-Tribune. Retrieved 7 August 2012.
  3. ↑ Elizabeth Malloy (September 22, 2006). "Room Temperature Storage Key to New Biotech's Ambition". San Diego Daily Transcript. Retrieved 19 August 2012.
  4. ↑ Blow, Nathan (2009). "Biobanking: freezer burn". Nature Methods. 6 (2): 173–178. doi: 10.1038/nmeth0209-173 .
  5. ↑ "Biomatrica Announces Acquisition by Exact Sciences". Biomatrica. 19 Oct 2018. Retrieved 28 Apr 2021.
  6. ↑ "James Flanigan (September 17, 2008). "Helping New Technologies Grow Into Businesses, the San Diego Way". The New York Times. Retrieved 08 August 2012.
  7. 1 2 3 4 "Biomatrica Corporate Facts Sheet" Archived April 2, 2015, at the Wayback Machine , Retrieved 08 March 2015
  8. ↑ "Biomatrica and Qiagen Enter Into Marketing Agreement for Shipment and Storage Products" Genetic Engineering News June 7, 2007. Retrieved August 20, 2012.
  9. 1 2 "QIAGEN’s New Product Line, QIAsafe DNA Blood, has been co-developed with Biomatrica and is based on Biomatrica’s SampleMatrix Technology" Archived 2013-02-01 at archive.today , Qiagen Press Release, Retrieved 08 August 2012.
  10. ↑ "Biostabilization Advances Enable Next-Gen Dx" Genetic Engineering News October 13, 2014. Retrieved April 8, 2015.
  11. ↑ "Biomatrica and USAMRIID Sign CRADA to Develop Biological Sample Stabilization Reagents" Genetic Engineering & Biotechnology News, July 28, 2011. Retrieved 08 August 2012.
  12. ↑ "SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research" Archived May 4, 2012, at the Wayback Machine SAIC News, May 31, 2011. Retrieved 08 August 2012
  13. ↑ "Biomatrica Secures Strategic Partnership Agreement with In-Q-Tel" Archived March 14, 2013, at the Wayback Machine Homeland Security News, February 23rd, 2011. Retrieved 08 August 2012
  14. ↑ staff reporter, GenomeWeb. "Biomatrica, ATCC Sign Licensing Deal". genomeweb.com. GenomeWeb LLC. Retrieved 9 March 2015.
  15. ↑ staff reporter, GenomeWeb. "Sigma-Aldrich to Distribute Biomatrica's Biospecimen Storage Products". genomeweb.com. GenomeWeb LLC. Retrieved 9 March 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.